ArticleOPEN ACCESS

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Blood
DOI: 10.1182/blood-2018-03-839688
36Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Langerak, A. W., Ritgen, M., Goede, V., Robrecht, S., Bahlo, J., Fischer, K., … Van Dongen, J. J. M. (2019, January 31). Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2018-03-839688

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free